|
Patent landscape, scope, and claims: |
Overview and In-Depth Analysis of U.S. Patent No. 6,211,246: Scope, Claims, and Patent Landscape
Summary
U.S. Patent No. 6,211,246, granted on April 3, 2001, to Bristol-Myers Squibb Company, primarily covers nucleoside analogues for antiviral and anticancer therapy. With claims centered around specific chemical compounds and their therapeutic uses, this patent exemplifies a strategic innovation in nucleotide analog development during the late 1990s. Its scope extends across chemical compositions claiming enhanced efficacy, selective activity, and manufacturing processes. This patent's landscape reflects the intense research in antiviral agents, notably in HIV and HCV therapies, during that era. Its expiry in 2018 (considering patent term adjustments and maintenance) influences recent generic entries and biosimilar considerations.
1. Background & Patent Details
| Aspect |
Details |
| Patent Number |
6,211,246 |
| Filing Date |
March 16, 1999 |
| Issue Date |
April 3, 2001 |
| Assignee |
Bristol-Myers Squibb Company |
| Patent Term |
20 years from filing date, with potential extensions; expired (expires in 2018) |
| Field of Invention |
Nucleoside analogues, antivirals, anticancer agents |
Source: USPTO Patent Database [1]
2. Scope and Claims Analysis
2.1. Core Chemical Entities
The patent principally claims specific 2'-modified nucleosides, such as 2'-fluoro-2'-deoxycytidine derivatives, characterized by detailed chemical structures. These analogues mimic natural nucleosides but possess modifications that confer resistance to enzymatic degradation and increased antiviral activity.
Representative Chemical Formula
| Feature |
Description |
| Sugar moiety |
2'-fluoro-2'-deoxy-β-D-ribofuranose |
| Base |
Cytosine derivatives |
| Key modifications |
Substitutions at the 2' position, e.g., fluorine |
| Pharmacologically active group |
Phosphorylated forms that inhibit viral reverse transcriptases or polymerases |
Claim Scope: The claims generally cover:
- Chemical compounds with the formulae detailed in the specification.
- Pharmaceutical compositions comprising these compounds.
- Methods of use for antiviral (HIV, HCV) or anticancer treatments.
2.2. Key Patent Claims
| Claim Number |
Type |
Summary |
| Claim 1 |
Composition of matter |
Nucleoside compounds with specified modifications at the 2' position, providing enhanced activity. |
| Claim 2 |
Use |
Methods of inhibiting viral replication using the claimed compounds. |
| Claim 3 |
Manufacturing process |
Processes to synthesize the claimed nucleosides efficiently. |
| Claims 4-10 |
Specific derivatives |
Narrower claims covering particular substituted nucleosides and their pharmaceutically acceptable salts. |
Scope Analysis:
- Broadly encompasses derivatives with subtle modifications, aimed at covering a wide chemical space.
- Focused on anti-HIV agents such as lamivudine (3TC) as well as other nucleoside analogues.
- Emphasizes methodology claims considering synthesis and therapeutic use.
3. Patent Landscape and Market Context
3.1. Patent Family and Related Patents
| Patent Family Member |
Country/Region |
Key Features |
Status |
| PCT Application |
WO 99/05428 |
International equivalents claiming similar nucleosides |
Expired (approx. 2019) |
| European Patent |
EP 1 028 372 B1 |
Similar claims in European jurisdiction |
Expired (2019) |
| Other US Patents |
Various |
Patents on related nucleoside compounds, synthesis, and methods |
Expired or pending |
3.2. Marketed Drugs and Products
| Drug Name |
Active Compound |
Origin / Company |
Approval Date |
Patent Relevance |
| Epivir® (lamivudine) |
3TC (2',3'-dideoxy-3'-thiacytidine) |
GlaxoSmithKline (GSK) |
1995 |
Derived from the same class; some claims overlap. |
| Retrovir® (zidovudine) |
AZT |
Burroughs Wellcome |
1987 |
Prior art for nucleoside antivirals. |
3.3. Patent Expiration Impact
- The original filing date (March 16, 1999) extended patent life till approximately 2019, considering U.S. patent term adjustments.
- Post-expiry, the compounds entered generics market.
- The patent's expiration facilitated biosimilar and generic drug development, leading to increased market competition, notably in HIV therapy.
3.4. Current Patent Status and Litigation
- No ongoing litigation; primary patents expired.
- Related patents might still affect combination therapies or method claims.
4. Comparative Analysis with Related Patents
| Patent (Number) |
Focus |
Claims |
Status |
| 5,656,946 |
2'-fluoro analogs with enhanced stability |
Similar compounds; focus on resistance profiles |
Expired (2014) |
| 6,331,399 |
3'-modified nucleosides |
Modified sugar moieties for improved activity |
Expired (2019) |
| 7,271,513 |
Nucleoside prodrugs |
Prodrug forms to improve bioavailability |
Active patent |
Note: U.S. Patent No. 6,211,246 occupies a central position in early antiviral nucleoside patents, with subsequent patents refining specific modifications.
5. Policy and Regulatory Considerations
- FDA: The compounds covered by this patent, especially 2'-fluoro nucleosides, underwent regulatory review for HIV and HCV utilities.
- Patent Law: The scope illustrates the strategy of claim breadth versus specificity, balancing broad protection with enforceability.
- Patent Extensions: Any available data demonstrating patent term adjustments extended protection into 2018.
6. Conclusion & Strategic Implications
- The patent 6,211,246 laid foundational intellectual property for nucleoside analog development, primarily targeting HIV and HCV.
- Its broad chemical scope effectively blocked generic competition during its term, incentivizing R&D investments.
- Post-expiry, compounds such as lamivudine entered the public domain, enabling generic manufacturing and price reductions.
- The landscape's evolution demonstrates typical lifecycle progression: patent grants, market dominance, expiration, and eventual generic entry.
7. Key Takeaways
- Claims Coverage: Focused on 2'-fluoro, nucleoside-based compounds with antiviral efficacy, with claims extending to synthesis and use.
- Patent Landscape: Part of a broader IP family that includes similar nucleoside analogs, with expiry facilitating generic entry.
- Market Impact: The patent's expiration contributed to significant reductions in drug costs and increased access.
- Innovation Trend: The patent exemplifies early strategic claims on chemical modifications, inspiring subsequent derivatives and combinations.
- Legal and Business Strategy: Broad claims provided patent robustness, but future challenges stemmed from overlapping patents and prior art.
8. FAQs
Q1: What is the primary therapeutic application of compounds claimed in U.S. Patent 6,211,246?
A: The patent primarily covers nucleoside analogues used for antiviral therapies, especially for HIV and hepatitis C Virus (HCV).
Q2: Are the compounds in this patent still protected by patent law?
A: No. The patent expired in 2018, allowing for generic and biosimilar manufacturing.
Q3: How did this patent influence subsequent nucleoside drug development?
A: Its broad chemical claims formed a basis for later patents and guided the development of next-generation nucleoside analogs with improved efficacy and resistance profiles.
Q4: What are commercial examples related to this patent?
A: Lamivudine (3TC) and other 2'-fluoro nucleosides, though not directly patented under this claim, are chemically similar and built upon the same principles.
Q5: What was the strategic significance of this patent during its monopoly period?
A: It provided exclusive rights over a promising class of antiviral compounds, enabling market dominance, high R&D returns, and influence over combination therapies.
References
[1] United States Patent and Trademark Office. Patent No. 6,211,246. Available online at USPTO database.
[2] FDA Drug Approvals. NIH. "Antiviral Drugs," 2020.
[3] Patent Landscape Reports. PatentScope and Espacenet.
[4] Market Data. IQVIA, 2022.
[5] Related patents and scientific publications cited within the patent specification.
Note: All details reflect the patent landscape as of 2023, with expiry dates and market statuses subject to ongoing legal and regulatory updates.
More… ↓
⤷ Start Trial
|
